8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
May 7, 2026·SEC
Ocugen, Inc.(OCGN)Earnings, Financials & Key Ratios
OCGN•NASDAQ
Price updated Jun 19, 2026
AboutOcugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.Show more
- Revenue$4M+8.8%
- EBITDA-$61M-14.7%
- Net Income-$68M-25.5%
- EPS (Diluted)-0.23-15.0%
- Gross Margin45.86%-10.9%
- EBITDA Margin-1371.56%-5.4%
- Operating Margin-1425.7%-5.6%
- Net Margin-1537.41%-15.3%
- ROE-776.89%-404.4%
OCGN Key Insights
Ocugen, Inc. (OCGN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 152.5%
✗Weaknesses
- ✗Profits declining 25.5% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 18 (bottom 18%)
- ✗Shares diluted 10.8% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when OCGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OCGN Price & Volume
Ocugen, Inc. (OCGN) stock price & volume — 10-year historical chart
Loading chart...
OCGN Growth Metrics
Ocugen, Inc. (OCGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years152.5%
3 Years21.05%
TTM-1.26%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-24.69%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-24.67%
Return on Capital
10 Years-128.28%
5 Years-110.58%
3 Years-119.53%
Last Year-154.72%
OCGN Recent Earnings
Ocugen, Inc. (OCGN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 6/12 qtrs (86%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.06-20.0%
$0.05
Rev
$2M+266.9%
$417,833
Q2 2026
Mar 4, 2026Metric
Actual
Est
EPS
$0.06+0.0%
$0.06
Rev
$193,000-118.0%
$1M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.07-21.7%
$0.06
Rev
$2M+298.2%
$440,000
Q3 2025
Aug 1, 2025Metric
Actual
Est
EPS
$0.05+16.7%
$0.06
Rev
$1M+357.7%
$300,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.06vs $0.05-20.0% | $2Mvs $417,833+266.9% |
| Q2 2026 | Mar 4, 2026 | $0.06vs $0.06+0.0% | $193,000vs $1M-118.0% |
| Q4 2025 | Nov 5, 2025 | $0.07vs $0.06-21.7% | $2Mvs $440,000+298.2% |
| Q3 2025 | Aug 1, 2025 | $0.05vs $0.06+16.7% | $1Mvs $300,000+357.7% |
Based on last 12 quarters of dataView full earnings history →
OCGN Peer Comparison
Ocugen, Inc. (OCGN) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 REPL | 841.41M | 10.19 | -3.32 | -102.69% | 0.18 | |||
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 ADVM | 96.26M | 4.36 | -0.66 | -72.22% | -189.84% | 1.30 | ||
 BOLD | 32.12M | 1.43 | -0.55 | -53.6% | 0.50 |
Compare OCGN vs Peers
Ocugen, Inc. (OCGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OCGN Income Statement
Ocugen, Inc. (OCGN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 43K | 0 | 2.49M | 6.04M | 4.05M | 4.41M | 4.46M |
Revenue Growth % | - | - | - | - | -100% | - | 142.6% | -32.82% | 8.83% | -1.26% |
Cost of Goods Sold | 1.53M | 49.62K | 8.09M | 6.35M | 0 | 0 | 704K | 1.97M | 2.39M | 0 |
COGS % of Revenue | - | - | - | 14776.74% | - | - | 11.66% | 48.53% | 54.14% | - |
Gross Profit | -1.53M▲ 0% | -49.62K▲ 96.8% | -8.09M▼ 16194.9% | -6.31M▲ 22.0% | 0▲ 100.0% | 2.49M▲ 0% | 5.33M▲ 114.3% | 2.09M▼ 60.9% | 2.02M▼ 3.0% | 4.46M▲ 0% |
Gross Margin % | - | - | - | -14676.74% | - | 100% | 88.34% | 51.47% | 45.86% | 100% |
Gross Profit Growth % | 8.31% | 96.77% | -16194.86% | 21.95% | 100% | - | 114.31% | -60.86% | -3.02% | - |
Operating Expenses | 24.95M | 25.84M | 6.08M | 14.97M | 58.03M | 91.56M | 70.86M | 56.84M | 64.94M | 70.72M |
OpEx % of Revenue | - | - | - | 34823.26% | - | 3680.02% | 1174.01% | 1401.82% | 1471.56% | - |
Selling, General & Admin | 9.38M | 10.2M | 6.08M | 7.97M | 22.92M | 35.4M | 31.99M | 26.69M | 27.58M | 29.24M |
SG&A % of Revenue | - | - | - | 18544.19% | - | 1422.83% | 530.05% | 658.1% | 624.95% | - |
Research & Development | 15.57M | 15.63M | 8.09M | 13.35M | 35.11M | 56.16M | 39.57M | 32.13M | 39.75M | 41.48M |
R&D % of Revenue | - | - | - | 31055.81% | - | 2257.19% | 655.62% | 792.26% | 900.75% | - |
Other Operating Expenses | -116K | 0 | -8.09M | -6.35M | 0 | 0 | -704K | -1.97M | -2.39M | 0 |
Operating Income | -24.95M▲ 0% | -30.11M▼ 20.7% | -14.16M▲ 53.0% | -21.29M▼ 50.3% | -58.03M▼ 172.6% | -89.07M▼ 53.5% | -65.53M▲ 26.4% | -54.76M▲ 16.4% | -62.92M▼ 14.9% | -66.25M▲ 0% |
Operating Margin % | - | - | - | -49500% | - | -3580.02% | -1085.67% | -1350.36% | -1425.7% | -1483.85% |
Operating Income Growth % | 17.68% | -20.67% | 52.96% | -50.29% | -172.62% | -53.5% | 26.43% | 16.44% | -14.9% | - |
EBITDA | -23.42M | -30.06M | -14.1M | -21.18M | -57.8M | -88.59M | -64.83M | -52.79M | -60.53M | -63.79M |
EBITDA Margin % | - | - | - | -49262.79% | - | -3560.73% | -1074.01% | -1301.82% | -1371.56% | -1428.6% |
EBITDA Growth % | 18.22% | -28.37% | 53.08% | -50.21% | -172.86% | -53.27% | 26.82% | 18.57% | -14.66% | -17.38% |
D&A (Non-Cash Add-back) | 1.53M | 49.62K | 61K | 102K | 229K | 480K | 704K | 1.97M | 2.39M | 2.47M |
EBIT | -26.41M | -14.47M | -14.16M | -14.29M | -58.03M | -89.07M | -65.53M | -54.76M | -62.92M | -67.38M |
Net Interest Income | 0 | 0 | -1.77M | -719.9K | -79K | 1.4M | 2.5M | 1.3M | -4.27M | -4.54M |
Interest Income | 0 | 0 | 1.21K | 1.06K | 0 | 1.4M | 2.5M | 1.3M | 922K | 483K |
Interest Expense | 134K | 163K | 1.77M | 720.96K | 79K | 0 | 0 | 0 | 5.19M | 5.02M |
Other Income/Expense | -1.46M | 11.89M | -6.08M | -537K | -389K | 2.27M | 2.45M | 703K | -4.93M | -5.42M |
Pretax Income | -26.41M▲ 0% | -8.64M▲ 67.3% | -20.24M▼ 134.2% | -21.82M▼ 7.8% | -58.42M▼ 167.7% | -86.8M▼ 48.6% | -63.08M▲ 27.3% | -54.05M▲ 14.3% | -67.85M▼ 25.5% | -71.67M▲ 0% |
Pretax Margin % | - | - | - | -50748.84% | - | -3488.91% | -1045.03% | -1333.02% | -1537.41% | -1605.22% |
Income Tax | -186K | -15.76M | 0 | 0 | -52K | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0.7% | 182.36% | 0% | 0% | 0.09% | 0% | 0% | 0% | 0% | 0% |
Net Income | -26.41M▲ 0% | -8.64M▲ 67.3% | -20.24M▼ 134.2% | -21.82M▼ 7.8% | -58.37M▼ 167.5% | -86.8M▼ 48.7% | -63.08M▲ 27.3% | -54.05M▲ 14.3% | -67.85M▼ 25.5% | -71.67M▲ 0% |
Net Margin % | - | - | - | -50748.84% | - | -3488.91% | -1045.03% | -1333.02% | -1537.41% | -1605.22% |
Net Income Growth % | -62.97% | 67.28% | -134.21% | -7.8% | -167.46% | -48.73% | 27.33% | 14.31% | -25.52% | -24.69% |
Net Income (Continuing) | -26.41M | -18.22M | -20.24M | -21.82M | -58.37M | -86.8M | -63.08M | -54.05M | -67.85M | -71.67M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -69.91▲ 0% | -13.98▲ 80.0% | -1.53▲ 89.1% | -0.31▲ 79.7% | -0.30▲ 3.2% | -0.40▼ 33.3% | -0.26▲ 35.0% | -0.20▲ 23.1% | -0.23▼ 15.0% | -0.22▲ 0% |
EPS Growth % | -3.45% | 80% | 89.06% | 79.74% | 3.23% | -33.33% | 35% | 23.08% | -15% | -24.67% |
EPS (Basic) | -69.91 | -13.98 | -1.53 | -0.31 | -0.30 | -0.40 | -0.26 | -0.20 | -0.23 | - |
Diluted Shares Outstanding | 377.84K | 618.18K | 13.89M | 112.24M | 195.01M | 214.6M | 244.33M | 271M | 300.17M | 320.42M |
Basic Shares Outstanding | 377.83K | 618.18K | 13.89M | 112.24M | 195.01M | 214.6M | 244.33M | 271M | 300.17M | 320.42M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
OCGN Balance Sheet
Ocugen, Inc. (OCGN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 8.18M | 16.4M | 15.77M | 25.88M | 102.65M | 98.49M | 42.97M | 61.68M | 24.34M | 38.55M |
Cash & Short-Term Investments | 7.98M | 15.54M | 7.44M | 24.04M | 94.96M | 90.93M | 39.46M | 58.51M | 18.57M | 31.86M |
Cash Only | 7.08M | 15.54M | 7.44M | 24.04M | 94.96M | 77.56M | 39.46M | 58.51M | 18.57M | 31.86M |
Short-Term Investments | 900K | 0 | 0 | 0 | 0 | 13.37M | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 122K | 172K | 7M | 0 | 0 | 7.56M | 3.51M | 3.17M | 5.77M | 6.7M |
Total Non-Current Assets | 2.86M | 1.03M | 1.04M | 1.5M | 3.12M | 10.14M | 21.58M | 20.76M | 19.18M | 18.35M |
Property, Plant & Equipment | 2.72M | 141K | 222.46K | 633K | 1.16M | 6.05M | 17.29M | 16.55M | 14.39M | 13.83M |
Fixed Asset Turnover | - | - | - | 0.07x | - | 0.41x | 0.35x | 0.24x | 0.31x | 0.30x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 137K | 150.48K | 151.02K | 0 | 0 | 0 | 0 | 0 | 0 | 634K |
Other Non-Current Assets | 0 | 736.52K | 667.75K | 865K | 1.95M | 4.09M | 4.29M | 4.21M | 4.78M | 4.21M |
Total Assets | 11.04M▲ 0% | 17.43M▲ 57.9% | 16.81M▼ 3.6% | 27.38M▲ 62.9% | 105.76M▲ 286.3% | 108.63M▲ 2.7% | 64.55M▼ 40.6% | 82.44M▲ 27.7% | 43.52M▼ 47.2% | 56.91M▲ 0% |
Asset Turnover | - | - | - | 0.00x | - | 0.02x | 0.09x | 0.05x | 0.10x | 0.08x |
Asset Growth % | -69.41% | 57.93% | -3.56% | 62.88% | 286.33% | 2.71% | -40.58% | 27.72% | -47.22% | -32.81% |
Total Current Liabilities | 3.81M | 2.87M | 4.54M | 3.61M | 7M | 28.53M | 17.09M | 21.59M | 23.04M | 20.71M |
Accounts Payable | 776K | 1.59M | 1.9M | 395K | 2.31M | 8.06M | 3.17M | 4.24M | 6.2M | 3.24M |
Days Payables Outstanding | 184.64 | 11.7K | 85.57 | 22.69 | - | - | 1.64K | 786.94 | 947.56 | - |
Short-Term Debt | 178K | 0 | 0 | 234K | 0 | 0 | 0 | 1.33M | 1.25M | 5.86M |
Deferred Revenue (Current) | 2.02M | 10M | 2.27M | 0 | 0 | 11.22M | 10.53M | 8.37M | 5.91M | 18.19M |
Other Current Liabilities | 1.18M | 948K | -2.06M | 1.68M | 1.72M | 3.11M | 1.03M | 5.25M | 6.69M | 11.61M |
Current Ratio | 2.15x | 5.71x | 3.47x | 7.16x | 14.66x | 3.45x | 2.51x | 2.86x | 1.06x | 1.86x |
Quick Ratio | 2.15x | 5.71x | 3.47x | 7.16x | 14.66x | 3.45x | 2.51x | 2.86x | 1.06x | 1.86x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 18.5M | 15.01M | 1.25M | 2.21M | 2.94M | 6.12M | 6.89M | 31.22M | 32.64M | 30.39M |
Long-Term Debt | 0 | 1.02M | 1.07M | 1.82M | 1.71M | 2.29M | 2.8M | 27.34M | 27.54M | 24.19M |
Capital Lease Obligations | 0 | 0 | 163.2K | 389K | 1.23M | 3.59M | 3.57M | 3.31M | 3.49M | 14.4M |
Deferred Tax Liabilities | 0 | -1.02M | 0 | 0 | 0 | 0 | 918K | 0 | 0 | 773K |
Other Non-Current Liabilities | 18.5M | 4M | 9.76K | 0 | 0 | 244K | 527K | 564K | 1.6M | 2.95M |
Total Liabilities | 22.3M | 17.89M | 5.79M | 5.83M | 9.94M | 34.65M | 23.98M | 52.81M | 55.68M | 51.1M |
Total Debt | 178K | 238K | 1.41M | 2.49M | 3.31M | 6.37M | 6.94M | 32.5M | 33.14M | 33.3M |
Net Debt | -6.9M | -15.3M | -6.04M | -21.55M | -91.65M | -71.19M | -32.52M | -26.01M | 14.57M | 1.44M |
Debt / Equity | - | - | 0.13x | 0.12x | 0.03x | 0.09x | 0.17x | 1.10x | - | 5.74x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.52x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.02x |
Interest Coverage | -197.12x | -88.77x | -8.01x | -19.81x | -734.53x | - | - | - | -12.13x | -13.42x |
Total Equity | -11.27M▲ 0% | -458K▲ 95.9% | 11.02M▲ 2505.8% | 21.55M▲ 95.6% | 95.82M▲ 344.6% | 73.98M▼ 22.8% | 40.56M▼ 45.2% | 29.63M▼ 27.0% | -12.17M▼ 141.1% | 5.8M▲ 0% |
Equity Growth % | -183.05% | 95.94% | 2505.77% | 95.58% | 344.63% | -22.79% | -45.17% | -26.95% | -141.06% | -377.85% |
Book Value per Share | -29.82 | -0.74 | 0.79 | 0.19 | 0.49 | 0.34 | 0.17 | 0.11 | -0.04 | 0.02 |
Total Shareholders' Equity | -11.27M | -458K | 11.02M | 21.55M | 95.82M | 73.98M | 40.56M | 29.63M | -12.17M | 5.8M |
Common Stock | 159K | 513K | 527.47K | 1.84M | 2M | 2.22M | 2.57M | 2.92M | 3.13M | 3.38M |
Retained Earnings | -208.19M | -216.83M | -51.48M | -73.3M | -131.67M | -223.09M | -286.17M | -340.22M | -408.07M | -427.24M |
Treasury Stock | 0 | 0 | -47.86K | -48K | -48K | -48K | -48K | -48K | -48K | -48K |
Accumulated OCI | -10.92M | -10.29M | 0 | 0 | 0 | 26K | 20K | 48K | 61K | 164K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OCGN Cash Flow Statement
Ocugen, Inc. (OCGN) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -23.02M | -15.78M | -16.89M | -14.71M | -47.94M | -60.08M | -62.05M | -42.14M | -56.96M | -59.4M |
Operating CF Margin % | - | - | - | -34206.35% | - | -2414.75% | -1028.06% | -1039.26% | -1290.82% | - |
Operating CF Growth % | 10.55% | 31.46% | -7.08% | 12.93% | -225.94% | -25.32% | -3.29% | 32.09% | -35.17% | -70.14% |
Net Income | -26.41M | -8.64M | -20.24M | -21.82M | -58.37M | -86.8M | -63.08M | -54.05M | -67.85M | -71.67M |
Depreciation & Amortization | 1.53M | 450K | 60.61K | 102.11K | 229K | 480K | 704K | 1.97M | 2.39M | 2.07M |
Stock-Based Compensation | 1.57M | 1.63M | 884.09K | 660K | 6.96M | 10.54M | 9.22M | 7.43M | 7.71M | 9.22M |
Deferred Taxes | 1.54M | -17.14M | 3.19M | 0 | -52K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -543K | 10.73M | 2.33M | 7.56M | 799K | 6.51M | 4.26M | -1.15M | 1.31M | 1.68M |
Working Capital Changes | -706K | -2.81M | -3.11M | -1.21M | 2.49M | 9.2M | -13.16M | 3.67M | -523K | -700K |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -1.21M | -375K | -1.63B | -540.85M | 3.5M | 0 | 0 | 0 | 0 | 0 |
Cash from Investing | -1.23M | -1.11M | -2.36M | -306.82K | -1.82M | -16.97M | 3.08M | -3.38M | -311K | -215K |
Capital Expenditures | -276K | -2.01M | -29.45K | -306.82K | -939K | -4.46M | -10.48M | -3.38M | -185K | -175K |
CapEx % of Revenue | - | - | - | 713.55% | - | 179.14% | 173.56% | 83.48% | 4.19% | 3.92% |
Acquisitions | 0 | 0 | -2.33M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | -273 | 0 | -877K | 761K | 0 | 0 | -126K | -40K |
Cash from Financing | -577K | 25.35M | 25.07M | 31.61M | 120.68M | 59.48M | 20.88M | 64.86M | 17.33M | 53.56M |
Debt Issued (Net) | -583K | -178K | 1.38M | -4.73M | -10K | 500K | 500K | 30M | -1M | -1M |
Equity Issued (Net) | 0 | 25.53M | 23.68M | 37.82M | 129.21M | 59.57M | 20.45M | 38.56M | 18.33M | 56.25M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | -48K | 0 | 0 | 0 | 0 | 0 | 0 | 245K |
Other Financing | 6K | 3K | 0 | -1.48M | -8.53M | -592K | -68K | -3.7M | 0 | -1.69M |
Net Change in Cash | -24.83M▲ 0% | 8.46M▲ 134.1% | 5.82M▼ 31.3% | 16.6M▲ 185.3% | 70.92M▲ 327.3% | -17.55M▼ 124.7% | -38.1M▼ 117.1% | 19.36M▲ 150.8% | -39.93M▼ 306.3% | -5.94M▲ 0% |
Free Cash Flow | -23.3M▲ 0% | -17.79M▲ 23.6% | -16.92M▲ 4.9% | -15.02M▲ 11.3% | -48.88M▼ 225.5% | -64.54M▼ 32.0% | -72.53M▼ 12.4% | -45.53M▲ 37.2% | -57.15M▼ 25.5% | -59.58M▲ 0% |
FCF Margin % | - | - | - | -34919.9% | - | -2593.89% | -1201.62% | -1122.74% | -1295.01% | -1334.29% |
FCF Growth % | 10.59% | 23.64% | 4.88% | 11.27% | -225.53% | -32.03% | -12.39% | 37.23% | -25.53% | -14.67% |
FCF per Share | -61.66 | -28.78 | -1.22 | -0.13 | -0.25 | -0.30 | -0.30 | -0.17 | -0.19 | -0.19 |
FCF Conversion (FCF/Net Income) | 0.87x | 1.83x | 0.83x | 0.67x | 0.82x | 0.69x | 0.98x | 0.78x | 0.84x | 0.83x |
Interest Paid | 30K | 1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 197K | 105K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OCGN Key Ratios
Ocugen, Inc. (OCGN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -2297.87% | - | -383.38% | -134.01% | -99.46% | -102.24% | -110.14% | -154.01% | -776.89% | -127987.5% |
Return on Invested Capital (ROIC) | - | - | - | -640.73% | -2088.84% | -1920.19% | -907.21% | -704.18% | -1565.59% | -885.47% |
Gross Margin | - | - | - | -14676.74% | - | 100% | 88.34% | 51.47% | 45.86% | 100% |
Net Margin | - | - | - | -50748.84% | - | -3488.91% | -1045.03% | -1333.02% | -1537.41% | -1605.22% |
Debt / Equity | - | - | 0.13x | 0.12x | 0.03x | 0.09x | 0.17x | 1.10x | - | 5.74x |
Interest Coverage | -197.12x | -88.77x | -8.01x | -19.81x | -734.53x | - | - | - | -12.13x | -13.42x |
FCF Conversion | 0.87x | 1.83x | 0.83x | 0.67x | 0.82x | 0.69x | 0.98x | 0.78x | 0.84x | 0.83x |
Revenue Growth | - | - | - | - | -100% | - | 142.6% | -32.82% | 8.83% | -1.26% |
Related:OCGN Dividend History·OCGN Revenue History·OCGN Price History·OCGN P/E History·OCGN Financial Ratios·OCGN Institutional Holders
OCGN SEC Filings & Documents
Ocugen, Inc. (OCGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
OCGN Frequently Asked Questions
Ocugen, Inc. (OCGN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Ocugen, Inc. (OCGN) reported $4.5M in revenue for fiscal year 2025. This represents a 17073% increase from $0.0M in 2012.
Ocugen, Inc. (OCGN) grew revenue by 8.8% over the past year. This is steady growth.
Ocugen, Inc. (OCGN) reported a net loss of $71.7M for fiscal year 2025.
Dividend & Returns
Ocugen, Inc. (OCGN) has a return on equity (ROE) of -776.9%. Negative ROE indicates the company is unprofitable.
Ocugen, Inc. (OCGN) had negative free cash flow of $59.6M in fiscal year 2025, likely due to heavy capital investments.